Quality by design (QbD) based development of a stability indicating HPLC method for drug and impurities

Journal of Chromatographic Science

Volumn 49, Issue 6, 2011, Pages 439-446

  Karmarkar, S ^a   Garber, R ^a   Genchanok, Y ^a   George, S ^a   Yang, X ^a   Hammond, R ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959445884     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chrsci/49.6.439     Document Type: Article

References (16)

1. International Conference on Harmonisation (ICH) Tripartite Guideline, ICH Q8(R2), August, 2009.
2. P. Gavin and B. Olsen. A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603). J. Pharm. Biomed. Anal. 46: 431-441 (2008).
3. M. Pohl, P. Borman, M. Schweitzer, K. Smith, G. Hansen, J. Larew, M. Hanna-Brown, and P. Nethercote. Implications and opportunities of applying the principles of QbD to analytical measurements. Pham. Tech. (Europe) 22: 29-37 (2010).
4. M. Schweitzer, M. Pohl, M. Hanna-Brown, P. Nethercote, P. Borman, G. Hansen, K. Smith, and J. Lare. Implications and opportunities of applying QbD principles to analytical measurements. Pham. Tech. 34: 52-59 (2010).
5. Y. Li, D. Liu, S. Yang, R. Sudini, M. McGuire, D. Bhanshali, and A. Kord. Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping. J. Pharm. Biomed. Anal. 52: 493-507 (2010).
6. J. Kochling, J. Bridgewater, and R. Naji. Pharmaceutical Stability Testing to Support Global Markets: Pharmasp. K.Huynh-Ba, Ed., 2010, 169.
7. S. Mecham and C. Rancourt. Applying QbD based on risk assessment to achieve a fundamental and practical understanding of method validation, presented at the IVT conference on Method Validation, San Francisco, July, 2010.
8. M. Enrique, E. Garcia-Montoya, M. Minarro, A. Orriols, J. Tico, J. Sune-Negre, and P. Perez-Lozano. Application of an experimental design for the optimization and validation of a new HPLC method for the determination of Vancomycin in extemporaneous ophthalmic solution. J. Chrom. Sci. 46: 828-834 (2008)
9. United States Pharmacopeia, General Chapter: 〈621〉, Chroma - tography, USP32, Rockville, Maryland, 2009.
10. S. Karmarkar, R. Miller, X. Yang, and R. Garber. Design of Forced Degradation Experiments to Demonstrate Specificity of Stability Indicating Methods for Pharmaceutical Injection Products, presented at the LC-GC PhamSep conference, Philadelphia, PA, 2009.
11. FDA Guidance for Industry, Analytical Procedures and Method Validation, CDER, August 2000.
12. J. Mehta and N. Vyas. Development & validation of stability indicating method for quantification of nebivolol & their related substances by HPLC-UV-PDA detection in its pharmaceutical drug product. Intl. J. Pharm. Tech. Res. 1: 1139-1147 (2009).
13. V. Godse, A. Bhosale, Y. Bafana, D. Borkar. Stability-indicating HPLC method for simultaneous determination of metoprolol succinate and hydrochlorothiazide in combination drug products. Intl. J. Chem. Sci. 7: 1733-1745 (2009).
14. M. Bakshi, S. Singh. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal. 28: 1011-1040 (2002). (Pubitemid 34607392)
15. International Conference on Harmonisation (ICH) Tripartite Guideline, ICH Q2(R1), October, 1994.
16. International Conference on Harmonisation (ICH) Tripartite Guideline, ICH Q1A(R2), February, 2003.